Advertisement

Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

  • Elodie Valade
  • Anne-Gaëlle DosneEmail author
  • Hong Xie
  • Robert Kleiman
  • Lilian Y. Li
  • Juan José Perez-Ruixo
  • Daniele Ouellet
Original Article
  • 43 Downloads

Abstract

Purpose

To characterize the effect of erdafitinib on electrocardiogram (ECG) parameters and the relationship between erdafitinib plasma concentrations and QTc interval changes in patients with advanced or refractory solid tumors.

Methods

Triplicate ECGs and continuous 12-lead Holter data were collected in the dose escalation part (Part 1) of the first-in-human study, with doses ranging from 0.5 to 12 mg. Triplicate ECG monitoring continued in Parts 2–4 where 2 dose regimens selected from Part 1 were expanded in prespecified tumor types. Analyses of ECG data included central tendency analyses, identification of categorical outliers and morphological assessment. A concentration–QTc analysis was conducted using a linear mixed-effect model based on extracted time matching Holter data.

Results

Central tendency, categorical outlier, and ECG morphologic analyses from 187 patients revealed no clinically significant effect of erdafitinib on heart rate, atrioventricular conduction or cardiac depolarization (PR and QRS), and no effect on cardiac repolarization (QTc). Concentration–QTc analysis from 62 patients indicated that the slopes of relationship between total and free erdafitinib plasma concentrations and QTcI (mean exponent of 0.395) were estimated as − 0.00269 ms/(ng/mL) and − 1.138 ms/(ng/mL), respectively. The predicted change in QTcI at the observed geometric mean of total and free concentration at the highest therapeutic erdafitinib dose (9 mg daily) was < 10 ms at the upper bound of the two-sided 90% confidence interval.

Conclusions

ECG data and the concentration–QTc relationships demonstrate that erdafitinib does not prolong QTc interval and has no effects on cardiac repolarization or other ECG parameters.

Clinical trial registration numbers NCT01703481, EudraCT: 2012-000697-34.

Keywords

Concentration–QTc modeling ECG analysis Erdafitinib Holter data Oncology QT interval 

Notes

Acknowledgements

Authors thank the study participants, without whom this study would never have been accomplished, and all the investigators, their medical, nursing and laboratory staff for their participation in this study. Erdafitinib (BALVERSA™, JNJ-42756493) was discovered in collaboration with Astex Pharmaceuticals. The authors also thank Dr. Himabindu Gutha (SIRO Clinpharm Pvt. Ltd.) for writing assistance, Dr. Harry Ma (Janssen Research & Development, LLC) for additional editorial support and Frederic Saad for helping with the creation of the dataset.

Study support: Janssen Research & Development, LLC, USA.

Author contributions

Hong Xie, Juan José Perez-Ruixo, Daniele Ouellet: conception and design; Elodie Valade, Anne-Gaëlle Dosne, Hong Xie, Daniele Ouellet: collection and assembly of data; Elodie Valade, Anne-Gaëlle Dosne, Hong Xie, Robert Kleiman, Lilian Y Li, Juan José Perez-Ruixo, Daniele Ouellet: data analysis and interpretation. Dr. Kleiman is an employee of eResearch Technology Inc. (ERT), Philadelphia. All other authors are/were employees of Janssen Research & Development and shareholders in the parent company (Johnson & Johnson).

All authors participated in the original design of the studies, supervising recruitment and monitoring of data quality, and contributed to the data interpretation, development and review of this manuscript and confirm that they have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. All authors meet ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors had access to the study data, provided direction and comments on the manuscript, made the final decision about where to publish these data and approved submission to this journal.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

280_2019_3896_MOESM1_ESM.docx (93 kb)
Supplementary material 1 (DOCX 93 kb)

References

  1. 1.
    ICH (E14) (2017) Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs—questions and answers (R3) guidance for industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf. Accessed Mar 2019
  2. 2.
    Chapel S, Hutmacher MM, Bockbrader H, de Greef R, Lalonde RL (2011) Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther 89(1):75–80.  https://doi.org/10.1038/clpt.2010.220 CrossRefGoogle Scholar
  3. 3.
    Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326–335.  https://doi.org/10.1002/cpt.60 CrossRefGoogle Scholar
  4. 4.
    Darpo B, Garnett C, Benson CT, Keirns J, Leishman D, Malik M, Mehrotra N, Prasad K, Riley S, Rodriguez I, Sager P, Sarapa N, Wallis R (2014) Cardiac safety research consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. Am Heart J 168(3):262–272.  https://doi.org/10.1016/j.ahj.2014.06.003 CrossRefGoogle Scholar
  5. 5.
    Darpo B, Nebout T, Sager PT (2006) Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human Use E14 guideline. J Clin Pharmacol 46(5):498–507.  https://doi.org/10.1177/0091270006286436 CrossRefGoogle Scholar
  6. 6.
    Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N (2014) The IQ-CSRC prospective clinical Phase 1 study: “Can early QT assessment using exposure response analysis replace the thorough QT study?”. Ann Noninvasive Electrocardiol 19(1):70–81.  https://doi.org/10.1111/anec.12128 CrossRefGoogle Scholar
  7. 7.
    Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JV (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48(1):13–18.  https://doi.org/10.1177/0091270007307881 CrossRefGoogle Scholar
  8. 8.
    Russell T, Riley SP, Cook JA, Lalonde RL (2008) A perspective on the use of concentration-QT modeling in drug development. J Clin Pharmacol 48(1):9–12.  https://doi.org/10.1177/0091270007311115 CrossRefGoogle Scholar
  9. 9.
    ICH Harmonised Tripartite Guideline (S7A) Safety pharmacology studies for human pharmaceuticals (2000) https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf. Accessed Apr 2019
  10. 10.
    Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV (2017) Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther 16(6):1010–1020.  https://doi.org/10.1158/1535-7163.mct-16-0589 CrossRefGoogle Scholar
  11. 11.
    FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma, April 2019. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm635910.htm. Accessed Apr 2019
  12. 12.
    Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC (2015) Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33(30):3401–3408.  https://doi.org/10.1200/jco.2014.60.7341 CrossRefGoogle Scholar
  13. 13.
    Piotrovsky V (2005) Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7(3):E609–E624.  https://doi.org/10.1208/aapsj070363 CrossRefGoogle Scholar
  14. 14.
    Bexton RS, Vallin HO, Camm AJ (1986) Diurnal variation of the QT interval–influence of the autonomic nervous system. Br Heart J 55(3):253–258CrossRefGoogle Scholar
  15. 15.
    Koch HJ, Raschka C, Banzer W (1999) Diurnal variation of ECG intervals and R or T amplitudes in healthy male subjects assessed by means of spectral and cosinor analysis. Jpn Heart J 40(1):45–53CrossRefGoogle Scholar
  16. 16.
    Oda E, Aizawa Y, Arai Y, Shibata A (1985) Diurnal variation of QT interval in patients with VVI pacemaker. Tohoku J Exp Med 145(4):419–426CrossRefGoogle Scholar
  17. 17.
    Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, Mehrotra D, Riley S, Sager P, Tornoe C, Wang Y (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383–397.  https://doi.org/10.1007/s10928-017-9558-5 CrossRefGoogle Scholar
  18. 18.
    Sarapa N, Britto MR (2008) Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7(3):305–318.  https://doi.org/10.1517/14740338.7.3.305 CrossRefGoogle Scholar
  19. 19.
    Bladder Cancer: Statistics. https://www.cancer.net/cancer-types/bladder-cancer/statistics. Accessed March 2019
  20. 20.
    Ferber G, Zhou M, Darpo B (2015) Detection of QTc effects in small studies–implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol 20(4):368–377.  https://doi.org/10.1111/anec.12227 CrossRefGoogle Scholar
  21. 21.
    Zhang J, Dang Q, Malik M (2013) Baseline correction in parallel thorough QT studies. Drug Saf 36(6):441–453.  https://doi.org/10.1007/s40264-013-0040-z CrossRefGoogle Scholar
  22. 22.
    Malik M, Hnatkova K, Batchvarov V (2004) Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation. Pacing Clin Electrophysiol 27(6 Pt 1):791–800.  https://doi.org/10.1111/j.1540-8159.2004.00530.x CrossRefGoogle Scholar
  23. 23.
    Chain AS, Krudys KM, Danhof M, Della Pasqua O (2011) Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. Clin Pharmacol Ther 90(6):867–875.  https://doi.org/10.1038/clpt.2011.202 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Janssen Research and DevelopmentBeerse, AntwerpBelgium
  2. 2.Janssen Research and DevelopmentSpring HouseUSA
  3. 3.eResearch Technology Inc. (ERT)PhiladelphiaUSA

Personalised recommendations